Comparative Pharmacology
Head-to-head clinical analysis: ASENDIN versus ENDEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASENDIN versus ENDEP.
ASENDIN vs ENDEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxapine, a dibenzoxazepine tricyclic antidepressant, primarily inhibits the reuptake of norepinephrine and serotonin. Its metabolite, 7-hydroxyamoxapine, exhibits dopamine D2 receptor antagonism, contributing to its antipsychotic effects.
Increases synaptic concentrations of serotonin and norepinephrine by inhibiting their reuptake in the central nervous system.
50 mg orally three times daily, increased gradually to 100-200 mg/day in divided doses. Max 300 mg/day.
Initial 75 mg/day orally in divided doses, increased gradually to 150-200 mg/day; maintenance 50-150 mg/day as single dose at bedtime or in divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours. Clinical context: Steady-state is reached within 5-7 days; the half-life supports once-daily dosing in most patients.
Terminal elimination half-life: 15-40 hours (mean ~24 h); clinical context: steady-state achieved in 5-7 days; prolonged in elderly and CYP2D6 poor metabolizers.
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (30-40%), with the remainder as other metabolites; <10% excreted unchanged in urine.
Renal: 70-80% as metabolites (including glucuronides, unchanged drug <5%); Biliary/Fecal: 20-30%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant